Experience

Davis Polk advised a sales agent in connection with the establishments of an SEC-registered at-the-market offering program by Millendo Therapeutics, Inc. of up to $50 million gross…

Davis Polk advised the joint book-running managers and the lead manager in connection with a $119 million public offering of common stock by NanoString Technologies, Inc. The common…

Davis Polk advised ShockWave Medical, Inc. on its SEC-registered initial public offering of 6,555,000 shares of common stock for an aggregate price to the public of approximately $111.4…

Davis Polk advised the underwriters in connection with the $345 million public offering of ordinary shares of Horizon Pharma plc. Horizon’s ordinary shares are listed on the NASDAQ Global…

Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering of €7 billion aggregate principal amount of notes by Medtronic Global…

Davis Polk advised the representatives of the underwriters in connection with the offering of $5.0 billion aggregate principal amount of notes issued by Merck & Co., Inc. The notes were…

Davis Polk advised CStone Pharmaceuticals in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in reliance on Rule 144A…

Davis Polk advised the joint book-running managers in connection with a $4.5 billion registered offering by Eli Lilly and Company of $1.15 billion aggregate principal amount of its 3.375%…

Davis Polk advised the joint book-running managers in connection with a $20 million SEC-registered common stock offering by Sienna Biopharmaceuticals, Inc. The common stock is listed on the…

Davis Polk advised the underwriters in connection with an initial public offering of 9,250,000 shares of common stock of Alector, Inc. at $19.00 per share, for total gross proceeds of $175…